Press release BoxID: 636577 (Xenios AG)
  • Xenios AG
  • Im Zukunftspark 1
  • 74076 Heilbronn
  • Contact person
  • Hilda Maria Bielz
  • +49 (7131) 2706-0

Xenios Pediatrics - Innovations for Pediatric Care

Because kids will be kids

(PresseBox) (Heilbronn, ) After founding Xenios AG earlier this year, Novalung GmbH and Medos Medizintechnik AG have now jointly started the Xenios Pediatrics business unit.

Xenios Pediatrics combines the leading extracorporeal systems from Medos and Novalung and thus creates a unique ECMO offering for pediatric intensive care. Neonates, babies and children with severe pulmonary or cardiac failure can be treated using extracorporeal membrane oxygenation (ECMO). With the help of this extracorporeal organ replacement procedure sufficient oxygenation can be maintained for days or weeks.

Based on years of experience in the field, Novalung and Medos have recognized the need for advanced extracorporeal therapy systems in pediatric and neonatal care. The next step is the decision to develop new system solutions together with the established pediatric ECMO centers.

Xenios Pediatrics focusses exclusively on the pediatric and neonatal field and offers a unique portfolio of products for patient-specific solutions for the entire spectrum of extracorporeal cardiopulmonary support. Xenios Pediatrics will continue to pursue a close working relationship with doctors and nurses to launch an innovation initiative for pediatric ECMO.

Website Promotion

Xenios AG

About Xenios Xenios is dedicated to translating medical need into pioneering therapies and devices together with caregivers and patients. The holding represents a fast paced, sustainable group of companies with a robust technology base and an ambitious product pipeline. Xenios strives to be the technology and market leader in extracorporeal therapies. The core technology platforms are artificial lungs, blood pumps, vascular access devices, temperature control, and biocompatible surfaces. The Xenios brands, Novalung, Medos and Xenios Pediatrics, provide extracorporeal therapy systems that respond to the medical need in pulmonary and cardiac failure. Xenios AG was founded in 2013 by Novalung GmbH and Medos AG.